PRIMARY OBJECTIVES:
I. Determine the maximum-tolerated dose (MTD) of GSK1120212 (trametinib) combined with
standard chemoradiation in unresectable non-small cell lung cancer (NSCLC) and safety as
measured by the rate of grade 3 or worse non-hematological toxicities occurring prior to the
beginning of consolidation therapy (including all toxicities attributed to chemoradiation
occurring within 10 weeks of the start of radiation therapy).
II. Pharmacokinetic (PK) analysis of carboplatin, paclitaxel, and trametinib.
SECONDARY OBJECTIVES:
I. Response rate based on computed tomography (CT) or fludeoxyglucose F 18 (FDG)-positron
emission tomography (PET)/CT imaging response assessment after completion of chemoradiation.
II. Biomarker correlate to response and resistance. III. Overall survival. IV. Patterns of
recurrence. V. Determine dose delay and the percentage of dose delivered for each agent.
OUTLINE: This is a dose-escalation study of trametinib.
CONCURRENT CHEMOTHERAPY: Patients undergo intensity-modulated radiation therapy (IMRT) or
three-dimensional conformal radiotherapy (3D-CRT) once daily (QD) 5 days a week for 6 weeks.
Patients receive trametinib orally (PO) QD and carboplatin intravenously (IV) over 30 minutes
and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of
disease progression or unacceptable toxicity. Patients without disease progression after
completion of chemoradiation proceed to consolidation chemotherapy.
CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation,
patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and
22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 4 months for 1 year, and then every 6 months for 2 years.
Inclusion Criteria:
- Patients must have histologically confirmed, newly diagnosed or recurrent from a
previously treated early stage lung cancers that are locally confined, non-small cell
lung cancers that are considered unresectable and for which chemoradiation will be
considered definitive therapy; patients with recurrent cancer that is amendable for
chemoradiation can be eligible only if patients with prior lobectomy for stage I
cancer had not had adjuvant chemotherapy, and more than 8 weeks have elapsed from
surgery to allow for wound healing; patients who recur from prior X-ray therapy (XRT)
or stereotactic body radiation therapy (SBRT) will not be eligible
- Patients must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional
techniques or as >= 10 mm with spiral CT scan, magnetic resonance imaging (MRI), or
calipers by clinical exam
- Prior thoracic radiation allowed only if there is minimal to no overlap with the
treatment area estimated at the time of consultation, and there is no cumulative
esophageal dose that exceeds more than 50% of the maximal acceptable dose tolerance
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
- Life expectancy of greater than 6 months
- Able to swallow and retain orally-administered medication and does not have any
clinically significant gastrointestinal abnormalities that may alter absorption such
as malabsorption syndrome or major resection of the stomach or bowels
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
- Hemoglobin >= 9 g/dL
- Platelets >= 100 x 10^9/L
- Albumin >= 2.5 g/dL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x
institutional ULN
- Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault
formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
- Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin
time (PTT) =< 1.5 x institutional ULN
- Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by
echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, during
the study participation, and for four months after the last dose of the drug; women of
child-bearing potential must have a negative serum pregnancy test within 14 days prior
to registration and agree to use effective contraception throughout the treatment
period and for 4 months after the last dose of study treatment; should a woman become
pregnant or suspect she is pregnant while she or her partner is participating in this
study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
- Activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (any G12, G13,
Q61) confirmed by Clinical Laboratory Improvement Act (CLIA)-certified testing
- The availability of formalin-fixed paraffin embedded archival tissue from core biopsy
of tumors is recommended for exploratory analysis
Exclusion Criteria:
- History of another malignancy
- Exception: patients who have been disease-free for 3 years, or patients with a
history of completely resected non-melanoma skin cancer and/or patients with
indolent secondary malignancies, are eligible; consult the Cancer Therapy
Evaluation Program (CTEP) Medical Monitor if unsure whether second malignancies
meet the requirements specified above
- History of interstitial lung disease or pneumonitis
- Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,
biologic therapy, or immunotherapy within 21 days prior to enrollment
- Use of other investigational drugs within 28 days (or five half-lives, whichever is
shorter; with a minimum of 14 days from the last dose) preceding the first dose of
trametinib and during the study
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO) or to
either carboplatin or paclitaxel
- Current use of a prohibited medication; the following medications or non-drug
therapies are prohibited:
- Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if
used as an appetite stimulant is allowed)
- Concurrent treatment with bisphosphonates is permitted; however, treatment must
be initiated prior to the first dose of study therapy; prophylactic use of
bisphosphonates in patients without bone disease is not permitted, except for the
treatment of osteoporosis
- Concurrent use of all herbal supplements is prohibited during the study
(including, but not limited to, St. John's wort, kava, ephedra [ma huang], gingko
biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)
- History or current evidence/risk of retinal vein occlusion (RVO)
- History or evidence of cardiovascular risk including any of the following:
- Left ventricular ejection fraction (LVEF) < LLN
- A QT interval corrected for heart rate using the Bazett's formula corrected QT
(QTcB) >= 480 msec
- History or evidence of current clinically significant uncontrolled arrhythmias
(exception: patients with controlled atrial fibrillation for > 30 days prior to
registration are eligible)
- History of acute coronary syndromes (including myocardial infarction and unstable
angina), coronary angioplasty, or stenting within 6 months prior to registration
- History or evidence of current >= class II congestive heart failure as defined by
the New York Heart Association (NYHA) functional classification system
- Treatment-refractory hypertension defined as a blood pressure of systolic > 140
mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive
therapy
- Known cardiac metastases
- Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with
chronic or cleared HBV and HCV infection are eligible); patients with human
immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements
- Pregnant women or nursing mothers; women of childbearing potential should be advised
to avoid pregnancy and use effective methods of contraception; men with a female
partner of childbearing potential must have either had a prior vasectomy or agree to
use effective contraception; if a female patient or a female partner of a patient
becomes pregnant while the patient receives trametinib, the potential hazard to the
fetus should be explained to the patient and partner (as applicable)
- HIV-positive patients on combination antiretroviral therapy are ineligible
- Patients who do not consent for PK studies to be performed (alternatively: patients
who initially consent to be on study but withdraws consent for PK study will be taken
off study and replaced)
